These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336 [TBL] [Abstract][Full Text] [Related]
3. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001 [TBL] [Abstract][Full Text] [Related]
4. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395 [TBL] [Abstract][Full Text] [Related]
5. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
6. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539 [TBL] [Abstract][Full Text] [Related]
8. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322 [TBL] [Abstract][Full Text] [Related]
9. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712 [TBL] [Abstract][Full Text] [Related]
10. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. Patel S; Freedman S; Chapman KL; Emms F; Fletcher AE; Knowles M; Marwood R; Mcallister G; Myers J; Curtis N; Kulagowski JJ; Leeson PD; Ridgill M; Graham M; Matheson S; Rathbone D; Watt AP; Bristow LJ; Rupniak NM; Baskin E; Lynch JJ; Ragan CI J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380 [TBL] [Abstract][Full Text] [Related]
11. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244 [TBL] [Abstract][Full Text] [Related]
12. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087 [TBL] [Abstract][Full Text] [Related]
13. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Zhang K; Davids E; Tarazi FI; Baldessarini RJ Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637 [TBL] [Abstract][Full Text] [Related]
15. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586 [TBL] [Abstract][Full Text] [Related]
16. The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. Feldpausch DL; Needham LM; Stone MP; Althaus JS; Yamamoto BK; Svensson KA; Merchant KM J Pharmacol Exp Ther; 1998 Jul; 286(1):497-508. PubMed ID: 9655895 [TBL] [Abstract][Full Text] [Related]
17. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337 [TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107 [TBL] [Abstract][Full Text] [Related]
19. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553 [TBL] [Abstract][Full Text] [Related]
20. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]